NEW YORK, Jan. 28 (GenomeWeb News) - Rick Episcopo has been appointed president of Genomics Collaborative, and John Boyce has been named senior director of business development, the company said today.
Additionally, Kevin Krenitsky, who has been senior vice president and medical director, will now be senior vice president, business development, the company said.
Both Episcopo and Boyce come to Genomics Collaborative, of Cambridge, Mass., from Sequenom. Episcopo was Sequenom's executive vice president of commercial operations between 2000 and 2003. Prior to that, he co-founded Cosmetic Therapeutics, a medically-based retail skin care store. Boyce was previously director of US sales at Sequenom. Prior to that, he was a territory manager for FMC/BioWhittaker.
David Allis, professor of in the laboratory of chromatin biology and epigenetics at Rockefeller University, has been awarded the third annual Wiley Prize in the biomedical sciences, the Wiley foundation said today.
Allis was selected for his "discovery that transcription factors can enzymatically modify histones to regulate gene activity," said Gunter Blobel, professor of cell biology at Rockefeller and chairman of the awards jury.
Allis, who recently joined Rockefeller from the University of Virginia Health System, where he was a professor of Biochemistry and Molecular Biology, will be invited to deliver a lecture on April 21 at Rockefeller as part of the award. The award also includes a $25,000 grant.
Curtis Van Tassell, a geneticist at the The United States Agricultural Research Service's Bovine Functional Genomics Laboratory in Beltsville, Md., has been awarded a Herbert L: Rothbart Outstanding Early Career Research Scientist of theYear award from ARS, the agency said last week.
Van Tassel is being honored for "conducting outstanding research to improve national genetic evaluation systems for dairy cattle and to identify genome regions affecting economically important health and productivity traits of cattle," the agency said.
Richard Gill has been appointed president of Signet Laboratories, the company said Jan 27.
Gill succeeds the company's founder, Ronald Casciato, who will become Executive Chairman. Gill comes to Signet, a Dedham, Mass., diagnostics and laboratory services firm, from Anvil, where he was president and CEO. Prior to joining Anvil, Gill was president and CEO of ActiveCyte, an intellectual property licensing solutions developer. He was also president and COO of Genome Therapeutics, and prior to that, senior vice president and general manager of BTG International of Philadelphia.
Zizi Fotev has signed on as chief business officer at Cenix BioScience, the company said Jan. 27.
Fotev comes to Cenix, of Dresden, Germany, from Atugen, where he previously served as vice president of business development. He has also worked as head of licensing and strategic alliances at Merck KGA Pharmaceuticals.
Cenix offers RNA interference research services.
Herbert Fritsche has joined the scientific advisory board of Health Discovery, of Waco Texas, the company said Jan. 27.
Fritsche is currently preofessor of laboratory medicine and chief of the clinical chemistry section at The University of Texas, M.D. Anderson Cancer Center in Houston, where he has been a researcher for 35 years.
Health Discovery is a pathway and biomarker discovery company that uses computational modeling to identify potential diagnostic and therapeutic targets.
John Dahler has been appointed Chief Financial Officer of Ambion, the company said Jan. 26.
Dahler, who will begin serving in this role on Feb. 2, comes to Ambion from Promega. He has also worked in finance positions at Fiskars Consumer Products and Pillsbury.
Ambion, of Austin, Texas, markets RNA-based research and diagnostic products.